BioLineRx (BLRX) FCF Margin (2024 - 2025)
BioLineRx (BLRX) recorded quarterly FCF Margin of 1649.48% in Q4 2025, down 234.44% quarter-over-quarter from 493.21% in Q3 2025, and down 157615.0% on a YoY basis from N/an in Q4 2024.
BioLineRx (BLRX) FCF Margin (2024 - 2025) Analysis & Trends
BioLineRx's FCF Margin history runs 2 years deep, the most recent figure standing at 1649.48% for Q4 2025.
- In Q4 2025, FCF Margin fell 157615.0% year-over-year to 1649.48%; the TTM figure through Dec 2025 stood at 684.24% (down 53282.0% YoY), while the FY2025 annual figure was 682.12%, down 53070.0% from the prior year.
- FCF Margin was 1649.48% for Q4 2025 at BioLineRx, down from 493.21% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 58.22% in Q2 2025 to a low of 1649.48% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -3.98% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | BioLineRx | 227.63 Mn | 211.90 Mn | 154,000.00 | -1,649.48% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1,649.48% |
| Sep 30, 2025 | -493.21% |
| Jun 30, 2025 | -58.22% |
| Mar 31, 2025 | -1,016.08% |
| Dec 31, 2024 | -73.33% |
| Sep 30, 2024 | -198.77% |
| Jun 30, 2024 | -209.57% |
| Mar 31, 2024 | -205.35% |